Dopaminergic neuron-specific SNCA-targeted epigenome therapy for precision medicine in Parkinson's disease
Conferences
O'donovan, B; Kantor, B; Rittiner, J; Chiba-Falek, O
Published in: MOLECULAR THERAPY
May 8, 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
May 8, 2026
Volume
34
Issue
5
Start / End Page
3455 / 3457
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
Citation
APA
Chicago
ICMJE
MLA
NLM
O’donovan, B., Kantor, B., Rittiner, J., & Chiba-Falek, O. (2026). Dopaminergic neuron-specific SNCA-targeted epigenome therapy for precision medicine in Parkinson's disease. In MOLECULAR THERAPY (Vol. 34, pp. 3455–3457).
O’donovan, Bernadette, Boris Kantor, Joseph Rittiner, and Ornit Chiba-Falek. “Dopaminergic neuron-specific SNCA-targeted epigenome therapy for precision medicine in Parkinson's disease.” In MOLECULAR THERAPY, 34:3455–57, 2026.
O’donovan B, Kantor B, Rittiner J, Chiba-Falek O. Dopaminergic neuron-specific SNCA-targeted epigenome therapy for precision medicine in Parkinson's disease. In: MOLECULAR THERAPY. 2026. p. 3455–7.
O’donovan, Bernadette, et al. “Dopaminergic neuron-specific SNCA-targeted epigenome therapy for precision medicine in Parkinson's disease.” MOLECULAR THERAPY, vol. 34, no. 5, 2026, pp. 3455–57.
O’donovan B, Kantor B, Rittiner J, Chiba-Falek O. Dopaminergic neuron-specific SNCA-targeted epigenome therapy for precision medicine in Parkinson's disease. MOLECULAR THERAPY. 2026. p. 3455–3457.
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
May 8, 2026
Volume
34
Issue
5
Start / End Page
3455 / 3457
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics